New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Stephen Mayo Biography and Net Worth

Director of Sarepta Therapeutics

Dr. Mayo is the Bren Professor of Biology and Chemistry at the California Institute of Technology (Caltech). He holds joint appointments in the Division of Biology and Biological Engineering and the Division of Chemistry and Chemical Engineering. He joined the Caltech faculty in 1992 and served as Vice Provost for Research (2007-2010) and Chair of the Division of Biology and Biological Engineering (2010-2020). Dr. Mayo's research focuses on the development of computational approaches to protein engineering – a field that has broad applications ranging from advanced biofuels to human therapeutics. In 2004, he was elected to the U.S. National Academy of Sciences for his pioneering contributions in the field of protein design.

Dr. Mayo has co-founded several companies: Molecular Simulations Inc. (now BIOVIA), Xencor, Inc. and, Protabit LLC, where he serves on the scientific advisory board. He is currently serving on the Merck Board of Directors and on the Scientific Advisory Board of Rubryc Therapeutics, Inc.

In addition to his academic and private-sector work, Dr. Mayo has held a number of significant positions including serving as an elected Board Member at the American Association for the Advancement of Science (2010-2014) and serving as a presidential appointee to NSF’s National Science Board (2013-2018).

Dr. Mayo received his undergraduate degree in chemistry from the Pennsylvania State University, his Ph.D. in chemistry from Caltech, and did postdoctoral work at both UC Berkeley and Stanford University School of Medicine.

What is Stephen Mayo's net worth?: The estimated net worth of Stephen Mayo is at least $734,004.06 as of March 5th, 2024. Dr. Mayo owns 6,621 shares of Sarepta Therapeutics stock worth more than $734,004 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Mayo may own. Learn More about Stephen Mayo's net worth.
How do I contact Stephen Mayo?: The corporate mailing address for Dr. Mayo and other Sarepta Therapeutics executives is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. Sarepta Therapeutics can also be reached via phone at (617) 274-4000 and via email at [email protected]. Learn More on Stephen Mayo's contact information.
Has Stephen Mayo been buying or selling shares of Sarepta Therapeutics?: Stephen Mayo has not been actively trading shares of Sarepta Therapeutics during the past quarter. Most recently, Stephen Mayo sold 3,135 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $122.96, for a transaction totalling $385,479.60. Following the completion of the sale, the director now directly owns 6,621 shares of the company's stock, valued at $814,118.16. Learn More on Stephen Mayo's trading history.
Who are Sarepta Therapeutics' active insiders?: Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?: In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 9 times. They sold a total of 78,532 shares worth more than $11,647,905.42. The most recent insider tranaction occured on August, 30th when CFO Ian Michael Estepan sold 5,985 shares worth more than $822,099.60. Insiders at Sarepta Therapeutics own 7.7% of the company. Learn More about insider trades at Sarepta Therapeutics.
Information on this page was last updated on 8/30/2024.

Stephen Mayo Insider Trading History at Sarepta Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/5/2024	Sell	3,135	$122.96	$385,479.60	6,621
11/17/2022	Sell	858	$109.92	$94,311.36	6,387

Stephen Mayo Buying and Selling Activity at Sarepta Therapeutics

Sarepta Therapeutics Company Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $110.86

$108.72

$111.38

50 Day Range

MA: $122.50

$104.54

$132.02

2 Week Range

Now: $110.86

$78.67

$173.25

Volume

1,195,494 shs

Average Volume

1,068,842 shs

Market Capitalization

$10.59 billion

P/E Ratio

88.69

Dividend Yield

N/A

Beta

0.81